| ESTUDIO EMPEROR-reduced (Packer et al., Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, N Engl J Med 2020;383:1413-24.) |
| ESTUDIO EMPA-RESPONSE (Damman et al., Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure, EHJ, 2020) |
| ESTUDIO SUGAR-DM-HF (Lee et al., Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction, Circulation, 2020 |
| ESTUDIO EMPA-TROPISM (Santos-Gallego et al., Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction, JACC, 2020 |
